Dementia and related illnesses are some of the worst in my books. Anything that can strip you of your memories and of who you are is just devastating for those that have it and those that are around them. There's a lot of good research being put into this and there have been some promising possibilities pop up in recent years.
Experimental Alzheimer's Drug Slows Mental Decline By 27% in Trial Hailed as 'Most Encouraging to Date'
It's not a full proof plan and doesn't stop it, but hindering its effects has to be considered a plus and step in the right direction.
Experimental Alzheimer's Drug Slows Mental Decline By 27% in Trial Hailed as 'Most Encouraging to Date'
Alzheimer’s advocates and researchers look forward to learning more about the data at a meeting in November, including participant safety and the percentage of patients who experienced any brain swelling.
“If those data are consistent with what we saw today regarding efficacy and safety, we strongly support FDA approval and full [Medicare] coverage,” added the AA in a statement.
“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease, and provide a clinically meaningful impact on cognition and function,” said Michel Vounatsos, Chief Executive Officer at Biogen.
The U.S. Food and Drug Administration (FDA) has agreed that the results of the 18-month trial can serve as the confirmatory study to verify the clinical benefit of lecanemab, setting a date of January 6 to announce its decision.
“If those data are consistent with what we saw today regarding efficacy and safety, we strongly support FDA approval and full [Medicare] coverage,” added the AA in a statement.
“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease, and provide a clinically meaningful impact on cognition and function,” said Michel Vounatsos, Chief Executive Officer at Biogen.
The U.S. Food and Drug Administration (FDA) has agreed that the results of the 18-month trial can serve as the confirmatory study to verify the clinical benefit of lecanemab, setting a date of January 6 to announce its decision.
Comment